News | September 22, 2008

Oropharyngeal Cancer Patients Show Less Salivary Gland Toxicity

September 23, 2008 – A multicenter trial testing intensity-modulated radiation therapy (IMRT) for patients with early stage oropharyngeal cancer showed a reduction in long-term salivary toxicity while achieving good tumor control according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG launched its phase I/II trial, RTOG 0022, to determine whether standardized dose and target definitions for IMRT could be accomplished in a multicenter setting. A total of 69 patients were entered on study from February 2001 through January 2005 from 14 academic and community institutions in the U.S. and Canada. A two-year local-regional control rate of 91 percent and a 49 percent rate of acute salivary gland toxicity (Grade 2) was reported by investigators compared with 80 and 84 percent in the same patient population from the RTOG database. The rate of salivary gland toxicity dropped to 23 percent at one year and 13 percent at two years. Evaluable patients who, at central review of their treatment plan, where found to have a major variation in their radiotherapy treatment plan had a significantly higher rate of local-regional failure than patients who were treated according to protocol (50 vs. 6 percent).

All institutions participating in the trial were pre-approved for IMRT by the Image-guided Therapy QA Center (ITC) at Washington University in St. Louis.

For more information: www.astro.org

Source: American Society For Therapeutic Radiology and Oncology

Related Content

SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Overall survival of metastatic patients with SABR presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
News | Radiation Oncology | October 30, 2018
October 30, 2018 — In the first randomized, phase II clinical trial of its kind, researchers have shown that an aggre
Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018

Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018.

Feature | Stereotactic Body Radiation Therapy (SBRT) | October 23, 2018 | By Greg Freiherr
With its shorter course of treatment,...
CyberKnife System Provides Excellent Prostate Cancer Survival Rates in Five or Fewer Sessions
News | Stereotactic Body Radiation Therapy (SBRT) | September 27, 2018
Accuray Inc. announced that published data from two prospective, multi-center studies using differing protocols provide...
First Patient Treated in Online Adaptive Radiotherapy Trial With CyberKnife System
News | Stereotactic Body Radiation Therapy (SBRT) | April 06, 2018
Accuray Inc. and Erasmus MC announced the first patient has been successfully treated using an online-adaptive (OA)...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
Age Impacts Post-treatment Mortality for Early-stage Lung Cancer Patients

Image courtesy of Henri Becquerel Cancer Center

News | Stereotactic Body Radiation Therapy (SBRT) | January 24, 2018
A University of Colorado Cancer Center study published in the Journal of Clinical Oncology explores mortality in the...
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
Elekta and Brainlab Offer Streamlined Workflow for Stereotactic Radiotherapy
News | Radiation Therapy | October 16, 2017
Elekta and Brainlab have reconfirmed their alliance for the integrated use of the Elekta Versa HD linear accelerator...